Ocular cicatricial pemphigoid: manifestations and management.
Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include: chronic cicatricial conjunctivitis, progressive conjunctival fibrosis, and corneal epitheliopathy. Systemic immunomodulatory therapy is the treatment of choice for controlling disease activity and limiting progression, given the systemic nature of the disease and the poor efficacy of current local or topical therapies. Systemic cyclophosphamide with short-term adjunctive high-dose prednisolone is the preferred treatment for severe and/or rapidly progressing OCP. Oral low-dose weekly methotrexate is a useful first-line treatment for mild-to-moderate OCP. The management of OCP requires a multidisciplinary approach to optimize the care of these patients.
Chang
John H
JH
Department of Ophthalmology, St. Vincent's Hospital, Level 10, 438 Victoria Street, Darlinghurst NSW 2010 Australia. iritis@ozemail.com.au
McCluskey
Peter J
PJ
D002921:Cicatrix / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005128:Eye Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010390:Pemphigoid, Benign Mucous Membrane / Q000150:complications*
D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008727:Methotrexate